Ewing's sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents. Currently accepted clinical prognostic factors fail to classify ES patients' risk to relapse at diagnosis. We aimed to find a new strategy to distinguish between poor and good prognosis ES patients already at diagnosis. We analysed the gene expression profiles of 14 primary tumor specimens and six metastases from ES patients, using oligonucleotide microarray analysis. The over-expression of two genes was validated by quantitative PCR using the LightCycler system. We identified two distinct gene expression signatures distinguishing high-risk ES patients that are likely to progress from low-risk ES patients with a favorable prognosis of long-term progression-free survival. The microarray-based classification was superior to currently used prognostic parameters. Over-expressed genes in the poor prognosis patients included genes regulating the cell cycle and genes associated with invasion and metastasis, while among the downregulated genes were tumor suppressor genes and inducers of apoptosis. Our results indicate the existence of a specific gene expression signature of outcome in ES already at diagnosis, and provide a strategy to select patients who would benefit from risk-adapted improved therapy.
Introduction
Ewing's sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents and it belongs to a group of neuroectodermal tumors known as Ewing's Sarcoma Family of Tumors (EFT). This is an aggressive tumor with a high propensity for recurrence and distant metastases (Ginsberg et al., 2002) . All EFT share specific translocations resulting in the fusion of the EWS gene on chromosome 22q12, a member of the TET family, with different ETS oncogenes on different chromosomes; the most frequent (B90%) is FLI1 on chromosome 11 (Burchill, 2003) . These translocations are considered distinct diagnostic features of ES tumors. An interesting finding was recently reported of Ewing tumors, which showed no evidence of an EWS gene rearrangement, but instead contained translocations involving the FUS gene at 16p11, another member of the TET family, with the ETS oncogene ERG at 21q22 (Shing et al., 2003) . The primary site of the tumor and initial response to therapy, assessed histologically as the degree of tumor necrosis following surgery, have become acceptable valid prognostic factors in localized tumors. In spite of advances in multimodal therapy, including combination of aggressive chemotherapy, radiotherapy and surgery, about 50% of patients eventually relapse, even after 5 years (Terrier et al., 1996) . Current clinical and biological characteristics fail to classify accurately ES patients according to their clinical behavior, and it is therefore essential to search for novel reliable prognostic parameters, already at diagnosis. The recent development of DNA microarrays provides an opportunity to take a genome wide approach to extend biological insights into the disease. Gene expression profiling using oligonucleotide high-density arrays has provided an additional tool for elucidating tumor biology as well as the potential for molecular classification of cancer (Khan et al., 2001; Nielsen et al., 2002; Yeoh et al., 2002) .
In this study, we used microarray analysis on primary tumors from localized, nonmetastatic ES patients, and applied supervised classification to identify a gene expression profile that could predict risk to relapse. Our results indicate the existence of a distinct gene expression signature of outcome in ES, already at diagnosis and provide a strategy to select patients who would benefit from risk-adapted novel therapy.
Results

Cluster analysis of gene expression profile
The study included 14 tumor samples from localized ES patients. All samples harbored the EWS/FLI-1 chimeric transcript. We compared the gene expression profile of seven tumors from patients who had tumor progression between 5 months up to 5 years from diagnosis (defined as high risk -HR) with seven tumors from patients who were disease free for a long period of follow-up (median 92 months; range 66-171) (defined as low risk -LR).
RNA was isolated from each tumor and hybridized to Affymetrix oligonucleotide high-density arrays U95Av2. We identified a subset of genes that distinguish between the two groups (HR and LR) by two steps. First, we selected for 8098 genes that were expressed in one of the groups, in at least three samples, and then we focused on 818 genes differentially expressed in either the HR or the LR groups (t-test; Po0.01).
In order to control false positive result as a consequence of multiple comparisons, we adjusted the P-values using false discovery rate (FDR) method (Benjamini and Hochberg, 1995) .
Using hierarchical clustering for prognosis profile, two distinct clusters could be determined: poor and good prognosis signatures (Figure 1) . All of the seven HR and six out of the seven LR patients (86%) were classified as poor and good prognosis signatures, respectively (Table 1) . One clinically LR patient who was disease free for a long period of follow-up (97 months) was classified in the poor prognosis signature group. The Kaplan-Meier life table analysis indicated that the patients predicted to have a good prognosis signature had a significantly improved progression-free survival (PFS) compared with those predicted to have a Figure 1 Hierarchical clustering of ES tumor samples. Illustration of the two-sided clusters dendogram, distinctly defining poor prognosis vs good prognosis groups of ES patients and the differentially expressed genes. Each column represents a patient and each row represents a gene. Overexpressed genes are depicted in red and downregulated genes are depicted in blue. Tumor sample numbers are marked on the x-axis, HR -high risk, LR -low risk, M -metastaes poor prognosis signature (100 vs 12.5%, respectively) ( Figure 2 , P ¼ 0.002).
Unsupervised analysis of metastases
We further tested six metastases, obtained from patients with localized disease who had tumor progression, using the unsupervised learning methodology, whether the poor and good prognosis signature set of genes can classify metastatic tissues to one of the prognostic groups, or as a distinct group.
We assumed that the metastases gene expression profile will not differ from the one observed for the primary tumors. Indeed, the expression pattern of the primary tumor and the metastases were indistinguishable.
Four metastases were identified as having a poor prognosis signature and two were classified as good prognosis signature (Figure 3 ).
Subclassification of differentially expressed genes
Additionally, we reordered the genes into two major clusters by performing hierarchical clustering of all signature genes. The two major groups correspond to overexpressed in the poor prognosis group and downregulated in the good prognosis group, and vice versa. These clusters could be further subdivided into six subclusters, corresponding to the variability of genes among the poor vs favorable prognosis signature patients, which was more considerable in the good prognosis group (Figure 4 ). Downregulated genes in the poor prognosis patients (three top subclusters) included tumor suppressor genes like FHIT, NEURL, LLGL1; inducers of apoptosis like TGFB1, TNFRSF12, CASP10; DNA repair genes: IGHMBP2, XRCC2; immune response genes: IL-2, IL1RL1, HLA-DOB; genes involved in cytoskeleton organization like MYO1C and COL6A1; cell adhesion molecules: CDH-2, ITGA2B, SCAM-1, ADAM15, ADAM19, ISLR; the estrogen receptor (ESR2), a signal transduction molecule, and others (Table 2) . Among the overexpressed genes in the poor prognosis patients (subclusters 4-6) were known markers of ES, like EWS breakpoint region 1 and beta 2 microglobulin, genes regulating the cell cycle like CDK2, E2F, RAF and MAPKs, and genes associated with invasion and metastasis like cadherin-11 and MTA1 (Table 3) .
Validation of overexpressed genes by RQ-PCR
Two genes that were significantly overexpressed in the poor prognosis signature group (Po0.01) attracted a particular attention; both are associated with invasion and metastasis. The first one is cadherin-11 (OB-cadherin), a homophilic calcium-dependent cell adhesion molecule, and the second is MTA1, tumor metastasis-associated gene. Cadherins modulate calcium ion-dependent cell-cell adhesion and are important in cell aggregation, migration and sorting (Takeichi, 1991) . Defective cell-cell and cellmatrix adhesion are among the hallmarks of cancer.
The MTA1 gene is a novel, highly conserved gene that encodes a nuclear protein product (Toh et al., 1994) .
Examination of the MTA1 protein suggests that it is a histone deacetylase and may serve multiple functions in cellular signaling, chromosome remodeling and transcription processes that are important in the progression, invasion and growth of metastatic cells (Nicolson et al., 2003) .
To validate the microarray data, these two overexpressed genes were analysed in further detail using reverse transcriptase-quantitative real-time PCR (RQ-PCR). Microarray-based expression and RQ-PCR-based expression data correlated significantly (Figure 5a and b). The mean log expression value of the poor prognosis signature group is significantly higher than that of the good prognosis signature group for both genes, cadherin-11 and MTA1, P ¼ 0.024 and P ¼ 0.003, respectively.
Discussion
In this study, we report the determination of highrisk ES patients and prediction of outcome using Figure 3 Gene expression profile of all ES samples including primary tumors (numbers in black) and metastases samples (numbers in red), HR -high risk, LR -low risk, M -metastaes. The expression pattern of the primary tumors and the metastases were indistinguishable oligonucleotide high-density array gene expression data with a supervised learning method. We identified gene expression signatures that distinguished HR ES patients that are likely to progress up to 5 years, from LR patients with a favorable prognosis of long-term PFS, between 5 and 14 years. The microarray-based classification of distinct risk groups was superior to currently used important prognostic parameters (Table 1) . Our results indicate that ES outcome can already be derived from the gene expression profile of the primary tumor, early at diagnosis.
Our results are compatible with recent reports indicating the ability to predict outcome, based on gene expression profile of the malignancy at diagnosis (Shipp et al., 2002; Yeoh et al., 2002) . In pediatric acute lymphoblastic leukemia, the gene expression profile identified prognostic leukemia subtypes, and identified patients who would eventually fail treatment (Yeoh et al., 2002) . A 'poor prognosis' signature was identified in breast cancer patients with a short interval to develop distant metastases , and the 5-year overall survival rates differed between the two groups of diffuse large B-cell lymphoma patients (Shipp et al., 2002) . Our data is in agreement with the observations reported recently for breast cancer (van't Veer et al., 2002) indicating that the ability to metastasize to distant sites is an early and inherent genetic property -already present at diagnosis. The report by Ramaswamy et al. (2003) further strengthens this hypothesis. They have detected a molecular program of metastasis that is shared by multiple solid tumor types, and are present in the primary tumor. These findings argue against the widely accepted previous theory that metastatic potential is acquired relatively late during multistep tumorigenesis (Bernards and Weinberg, 2002) .
One of the most common and important mechanisms in the transformation of normal cells into malignant cells is the inactivation of one or more tumor suppressor genes.
The fragile histidine triad (FHIT) gene is a tumor suppressor gene that belongs to the histidine triad family of nucleoside-binding proteins. Numerous studies have indicated that FHIT gene expression is often altered in tumor cells from many malignancies, and successful FHIT gene therapy was performed in mouse models, in lung carcinoma and in tumor cell cultures (Fouts et al., 2003) . In this study, we report for the first time the Figure 4 The two major gene clusters and the six subclusters formed on the basis of hierarchical clustering of all signature genes. The two gene clusters consist of differentially expressed genes: overexpressed in the poor prognosis group and downregulated in the good prognosis group, and vice versa. Representative genes of each subcluster are shown downregulation of FHIT in ES, and its differential expression between poor and good prognosis patients. These findings may propose FHIT as a potential target for therapeutic intervention.
The EWS-FLI1 oncogene was found to repress expression of TGFbRII and may account for decreased TGF-b responsiveness. Moreover, other EWS fusion genes, such as EWS-ERG and EWS-ETV1, also repress TGF-bRII expression (Im et al., 2000) . This data along with the fact that TGF-bI was downregulated in the poor prognosis patients and significantly differentiated between the two groups, may suggest that inactivation of TGF-b may be an important step in ES tumorigenesis and associated with a more aggressive disease.
Estrogen receptor b (ER b) expression was observed to be significantly decreased in breast cancer and metastatic lymph node tissues compared with normal mammary and benign breast tumors (Park et al., 2003 ). An inverse relationship was found between ER b mRNA level and both histologic grade and progesterone receptor expression. The same results were presented in our study, significantly decreased expression of ER b and overexpression of progesterone receptor and of a repressor of estrogen receptor activity (REA), in the poor prognosis patients. These observations might imply of an involvement of the estrogen receptor pathway in the tumorigenesis of ES, similar to breast cancer.
Cell adhesion molecules are thought to play a significant role not only in maintaining tissue architecture, but also in tumor progression, which includes change in morphology, invasion and metastasis. Disruption of the cadherin-catenin complex and the loss of the E-cadherin expression has been demonstrated in carcinomas arising in several tissues including prostate (Bussemakers et al., 2000) , gastric (Shibata et al., 1996) and breast carcinomas (Pishvaian et al., 1999) , and has been correlated with various pathologic and clinical features, such as tumor differentiation, proliferation and a poor patient prognosis (Hajra and Fearon, 2002) .
N-cadherin and cadherin-11 are expressed during embryonic development in mesenchymal cells and are believed to participate in chondro-osteogenic cell condensation in somites and limb buds (Oberlender and Tuan, 1994) . The distribution of these two cadherins largely overlaps during embryogenesis, although cadher- Figure 5 Correlation between expression of the cadherin-11 and the MTA1 genes by microarray analysis and by real-time PCR. (a) Expression mean log value of cadherin-11 in poor prognosis patients was significantly higher than the expression mean log value in good prognosis patients by both analyses. (b) Gene expression pattern in the poor and good prognosis patients was also significantly correlated by both analyses, for the MTA1 gene in-11 is particularly abundant in areas undergoing chondrogenesis. Cadherin-11 expression is downregulated in differentiated structures (Shin et al., 2000) . Cadherin-11 was highly expressed in embryonal and alveolar rhabdomyosarcoma, while it was downregulated in normal skeletal muscle. This data suggest that cadherin-11 might be involved in myogenesis and that rhabdomyosarcoma may re-express or fail to downregulate cadherin-11 (Markus et al., 1999) . Similarly, in Wilms' tumors, there was a strong expression of cadherin-11, and in several cases it was inversely correlated with the expression of E-cadherin (Schulz et al., 2000) . In our microarray-based analysis, overexpression of cadherin-11 on one hand, and downregulation of Ncadherin, on the other hand, discriminated between HR and LR ES patients. The overexpression of cadherin-11 was validated by RQ-PCR. Based on our results and on the observations reported for rhabdomyosarcoma and Wilms' tumor, we propose that in tumors originated from mesenchymal cells, N-cadherin functions as the Ecadherin in epithelial cells, and therefore the downregulation of N-cadherin and overexpression of cadherin-11 facilitate the invasive properties of sarcoma cells.
It was recently found, by Mahoney et al. (2002) that MTA1 gene expression is associated with migration and invasion and it is involved in the metastatic process. The MTA1 gene was found to be overexpressed in a variety of cancerous tissues including breast, esophageal, colorectal, gastric and pancreatic carcinomas (Toh et al., 1997 (Toh et al., , 1999 Iguchi et al., 2000; Nawa et al., 2000a) . The MTA1 protein is likely a nuclear regulatory protein, and it might interact with specific genes involved in cellular regulation (Nicolson et al., 2003) . Antisense oligonucleotide treatment of breast cancer cell lines that showed high levels of expression of the MTA1 gene inhibited the cell growth and in vitro invasion (Nawa et al., 2000b) . Therefore, MTA1 gene might be used as a therapeutic target. It was also reported that MTA1 represses ER transcription by recruiting histone deacetylases to the estrogen receptor element (ERE)-containing target gene chromatin in breast cancer cells (Mishra et al., 2003) . Here we report, for the first time, the overexpression of the MTA1 gene in ES. Furthermore, it was one of the genes that distinguished between HR and LR patients and its overexpression was also confirmed by RQ-PCR.
The process of invasion and metastasis is a defined phenotype of a malignant neoplasm and the principal cause of cancer-treatment failure. These findings support the emerging notion that the clinical outcome of individuals with cancer can be predicted using the gene expression profiles of primary tumors (Alizadeh et al., 2000; . Thus, it was not surprising that 67% of the metastases were classified in the poor prognosis signature group, indistinguishable from the primary tumors, since the 'metastasis profile' is present already at diagnosis.
We are aware that our report consists of a small sample size, even so, the highly significant results distinguishing the two clinical prognostic groups are remarkable. The microarray analysis could distinguish favorable vs unfavorable ES patients, regardless of clinical parameters. This study should be the basis for an extended investigation of ES tumors, which may lead to the development of an important prognostic tool.
Our data imply that classification of patients into high-and low-risk subgroups may be useful in selecting ES patients who would benefit from early intensive or reduction of systemic adjuvant treatment, reducing overtreatment associated with undesirable side effects and augment undertreatment. Furthermore, genes that are overexpressed in tumors with a poor prognosis profile are potential targets for the development of new rational cancer therapy.
Materials and methods
Patient samples
A total of 14 primary tumor specimens and six metastases were obtained from 18 ES patients with nonmetastatic disease. Of one patient, both primary and recurrent tumors were analysed (SA37 and SA43), and two metastases were taken from another patient, six years apart (SA45 and SA46). All patients were admitted to the Pediatric Hematology Oncology Department at Schneider Children's Medical Center. Informed consent was obtained from the patients or their guardians, and the local and National Ethics Committees approved the research project. All patients were treated with a combination of aggressive chemotherapy, radiotherapy and surgery. The median age at diagnosis was 15 years (range 7-27). Five patients were female and 13 were male subjects. Response to therapy was defined by histopathological response and assessed by percentage of tumor necrosis at the time of surgery (limb salvage procedure) following neoadjuvant chemotherapy and radiotherapy. The median follow-up was 72.5 months (range 7-171). Tumors were snap-frozen in liquid nitrogen immediately after surgery and stored at À801C until use.
Microarray hybridization
Total RNA (10 mg) was extracted from each tumor using Tri Reagent (Molecular Research Center, Inc. Cincinnati, OH, USA). Double-stranded cDNA was generated using the SuperScript Choice System (Gibco Brl, Rockville, MD, USA), using an oligo(dT) 24 primer containing a T7 promoter site at the 3 0 end (Genset, La Jolla, CA, USA) and purified via a phenol-chloroform extraction followed by an ethanol precipitation. Purified cDNA was used as a template for in vitro transcription (IVT), which was performed with T7 RNA polymerase and biotin-labeled ribonucleotides, using the ENZO BioArray High Yield RNA Transcript Labeling Kit (Enzo Diagnostics, New York, NY, USA) and purified over RNeasy mini columns (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions, and the labeled cRNA was fragmented in fragmentation buffer. A mixture of four control bacterial and phage cRNA was included to serve as an internal control for hybridization efficiency.
In total, 12 mg cRNA of each sample were hybridized to a Genechip Human Genome U95Av2 array (Affymetrix, Santa Clara, CA, USA). After hybridization, each array was washed according to procedures developed by the manufacturer (Affymetrix), and stained with streptavidin-phycoerythrin conjugate (Molecular Probes, Eugene, OR, USA). The hybridization signal was amplified by using biotinylated antistreptavidin antibodies (Vector Laboratories, Burlingame, CA, USA), followed by restaining with streptavidin-phycoerythrin. The expression value for each gene was determined by calculating the average differences of the probe pairs in use for that gene.
Two samples were analysed in duplicate and results were reproducible.
Data analysis Normalization and filtering
The microarray results were analysed using the GeneSpring Software s . Normalization was performed by setting expression values lower than zero to zero and then each measurement was divided by the median of all measurements in that sample.
In order to filter out genes that are not expressed in any of the groups, we used Affymetrix absolute call (MAS 4.0: P, Mexpressed genes, A -not expressed). Genes that were expressed in one group were defined as genes expressed in at least three samples.
Selecting for differentially expressed genes A Student's t-test was applied for each gene, and genes with an adjusted P-value less then 0.01 were selected as differentially expressed genes. Pvalues were corrected to reduce false positive using Benjamini and Hochberg False Discovery Rate (Benjamini and Hochberg, 1995) .
Hierarchical clustering A divisive hierarchical clustering was performed as described by Eisen et al. (1998) , using centered correlation as measurment distance.
PFS analysis
The Kaplan-Meier PFS analysis, using the log rank test, was performed in order to correlate the microarray classification results with patients' clinical outcome.
Quantitative real-time PCR (RQ-PCR)
The microarrayderived expression data was evaluated for the cadherin-11 and MTA1 genes using quantitative PCR by the LightCycler system (Roche Diagnostics, Mannheim, Germany). In all, 3 mg of total RNA was processed to cDNA by the Reverse Transcription System (Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol. The cDNA was purified with GFX PCR DNA and Gel Band Purification kit (Amersham Biosciences, Piscataway, NJ, USA). Double-stranded cDNA (5 ml) was amplified in a 20 ml reaction containing 4 mM MgCL 2, 10 mM of each primer and LightCycler -FastStart DNA Master SYBR Green I mix (Roche Diagnostics). Gene expression of the house-keeping gene porphobilinogen deaminase (PBGD) was used as a control. The mean log expression of poor prognosis samples was compared with the mean log expression of good prognosis samples by Student's t-test. The primers used for Cadherin-11 gene amplification were: sense 5 0 -AGAGGCCTACATTCT GAACG-3 0 and antisense 5 0 -TTCTTTCTTTTGCCTTCTC AGG-3 0 , and for the MTA1 gene amplification: sense 5 0 -AG CTACGAGCAGCACAACGGGGT-3 0 and antisense 5 0 -CAC GCTTGGTTTCCGAGGAT-3 0 . All reactions were performed in duplicate. Quantitative analysis was performed using the LightCycler Software. The specificity of the PCR products was determined with the LightCycler Software's melting-curve analysis feature.
